We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Add DaVita (DVA) to Your Portfolio
Read MoreHide Full Article
DaVita Inc. (DVA - Free Report) has been gaining from its business model. The optimism led by a solid fourth-quarter 2023 performance and the acquisition of dialysis centers are expected to contribute further. However, concerns regarding its dependence on commercial payers and macroeconomic challenges persist.
Over the past year, this Zacks Rank #1 (Strong Buy) stock has gained 57.8% compared with a 15.7% rise of the industry and 27.4% growth of the S&P 500.
The renowned global comprehensive kidney care provider has a market capitalization of $11.71 billion. The company projects 12.1% growth for the next five years and expects to maintain its strong performance. DaVita’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average surprise being 35.6%.
Image Source: Zacks Investment Research
Let’s delve deeper.
Business Model: Investors are optimistic about DaVita’s patient-centric care model, which leverages its platform of kidney care services to maximize patient choice in both models and modalities of care. Value-based arrangements are proliferating in the kidney health space. These arrangements allow for a much larger degree of collaboration between nephrologists, providers and transplant programs, resulting in a more complete understanding of each patient’s clinical needs. Per management, this is expected to lead to better care coordination and earlier intervention.
Acquisition of Dialysis Centers: Acquiring dialysis centers and businesses that own and operate dialysis centers as well as other ancillary services is DaVita’s preferred business strategy. These strategies have boosted the company’s top line to a large extent, raising investors’ optimism.
As of Dec 31, 2023, DaVita provided dialysis services to around 250,200 patients at 3,042 outpatient dialysis centers, of which 2,675 were U.S. centers while 367 were located across 11 other countries. During the fourth quarter of 2023, the company opened a total of two new dialysis centers in the United States and acquired eight dialysis centers outside the United States.
Strong Q4 Results: DaVita’s solid fourth-quarter 2023 results buoy optimism. The company registered an uptick in overall top line and dialysis patient service and Other revenues. DaVita also recorded a per-day increase in total U.S. dialysis treatments during the fourth quarter on a sequential basis.
Downsides
Dependence on Commercial Payers: A significant portion of DaVita’s dialysis and related lab services revenues are generated from patients who have commercial payers as the primary payers. The payments received from commercial payers are the primary generators of profit. However, there remains a risk of people shifting from commercial insurance schemes to government schemes due to the wide disparity in payment rates in case of a rise in unemployment.
Macroeconomic Concerns: DaVita's business is significantly impacted by various global economic and market conditions. These include challenges from the COVID-19 pandemic, inflation, rising interest rates, labor market difficulties and supply-chain disruptions. The ongoing conflict between Russia and Ukraine exacerbates these issues, contributing to widespread uncertainty and volatility.
Estimate Trend
DaVita is witnessing a positive estimate revision trend for 2024. In the past 90 days, the Zacks Consensus Estimate for its earnings has moved 9.1% north to $9.23.
The Zacks Consensus Estimate for the company’s first-quarter 2024 revenues is pegged at $3.01 billion, suggesting a 4.8% uptick from the year-ago quarter’s reported number.
Other Key Picks
A few other top-ranked stocks in the broader medical space are LeMaitre Vascular, Inc. (LMAT - Free Report) , Cardinal Health, Inc. (CAH - Free Report) and Ecolab Inc. (ECL - Free Report) .
LeMaitre Vascular, sporting a Zacks Rank of 1 at present, has an estimated long-term growth rate of 14%. LMAT’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 8.9%. You can see the complete list of today’s Zacks #1 Rank stocks here.
LeMaitre Vascular’s shares have rallied 24.9% compared with the industry’s 3.5% rise in the past year.
Cardinal Health, carrying a Zacks Rank of 2 (Buy) at present, has an estimated long-term growth rate of 14.2%. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average being 15.6%.
Cardinal Health has gained 34.6% compared with the industry’s 8.9% rise in the past year.
Ecolab, sporting a Zacks Rank of 1 at present, has an estimated long-term growth rate of 13.3%. ECL’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 1.7%.
Ecolab’s shares have rallied 34.8% against the industry’s 5.5% decline in the past year.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Here's Why You Should Add DaVita (DVA) to Your Portfolio
DaVita Inc. (DVA - Free Report) has been gaining from its business model. The optimism led by a solid fourth-quarter 2023 performance and the acquisition of dialysis centers are expected to contribute further. However, concerns regarding its dependence on commercial payers and macroeconomic challenges persist.
Over the past year, this Zacks Rank #1 (Strong Buy) stock has gained 57.8% compared with a 15.7% rise of the industry and 27.4% growth of the S&P 500.
The renowned global comprehensive kidney care provider has a market capitalization of $11.71 billion. The company projects 12.1% growth for the next five years and expects to maintain its strong performance. DaVita’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average surprise being 35.6%.
Image Source: Zacks Investment Research
Let’s delve deeper.
Business Model: Investors are optimistic about DaVita’s patient-centric care model, which leverages its platform of kidney care services to maximize patient choice in both models and modalities of care. Value-based arrangements are proliferating in the kidney health space. These arrangements allow for a much larger degree of collaboration between nephrologists, providers and transplant programs, resulting in a more complete understanding of each patient’s clinical needs. Per management, this is expected to lead to better care coordination and earlier intervention.
Acquisition of Dialysis Centers: Acquiring dialysis centers and businesses that own and operate dialysis centers as well as other ancillary services is DaVita’s preferred business strategy. These strategies have boosted the company’s top line to a large extent, raising investors’ optimism.
As of Dec 31, 2023, DaVita provided dialysis services to around 250,200 patients at 3,042 outpatient dialysis centers, of which 2,675 were U.S. centers while 367 were located across 11 other countries. During the fourth quarter of 2023, the company opened a total of two new dialysis centers in the United States and acquired eight dialysis centers outside the United States.
Strong Q4 Results: DaVita’s solid fourth-quarter 2023 results buoy optimism. The company registered an uptick in overall top line and dialysis patient service and Other revenues. DaVita also recorded a per-day increase in total U.S. dialysis treatments during the fourth quarter on a sequential basis.
Downsides
Dependence on Commercial Payers: A significant portion of DaVita’s dialysis and related lab services revenues are generated from patients who have commercial payers as the primary payers. The payments received from commercial payers are the primary generators of profit. However, there remains a risk of people shifting from commercial insurance schemes to government schemes due to the wide disparity in payment rates in case of a rise in unemployment.
Macroeconomic Concerns: DaVita's business is significantly impacted by various global economic and market conditions. These include challenges from the COVID-19 pandemic, inflation, rising interest rates, labor market difficulties and supply-chain disruptions. The ongoing conflict between Russia and Ukraine exacerbates these issues, contributing to widespread uncertainty and volatility.
Estimate Trend
DaVita is witnessing a positive estimate revision trend for 2024. In the past 90 days, the Zacks Consensus Estimate for its earnings has moved 9.1% north to $9.23.
The Zacks Consensus Estimate for the company’s first-quarter 2024 revenues is pegged at $3.01 billion, suggesting a 4.8% uptick from the year-ago quarter’s reported number.
Other Key Picks
A few other top-ranked stocks in the broader medical space are LeMaitre Vascular, Inc. (LMAT - Free Report) , Cardinal Health, Inc. (CAH - Free Report) and Ecolab Inc. (ECL - Free Report) .
LeMaitre Vascular, sporting a Zacks Rank of 1 at present, has an estimated long-term growth rate of 14%. LMAT’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 8.9%. You can see the complete list of today’s Zacks #1 Rank stocks here.
LeMaitre Vascular’s shares have rallied 24.9% compared with the industry’s 3.5% rise in the past year.
Cardinal Health, carrying a Zacks Rank of 2 (Buy) at present, has an estimated long-term growth rate of 14.2%. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average being 15.6%.
Cardinal Health has gained 34.6% compared with the industry’s 8.9% rise in the past year.
Ecolab, sporting a Zacks Rank of 1 at present, has an estimated long-term growth rate of 13.3%. ECL’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 1.7%.
Ecolab’s shares have rallied 34.8% against the industry’s 5.5% decline in the past year.